Corbus Offers Upside Despite Post-FDA Update, Analyst Highlights Competitive Edge

All NewsApril 7, 2026

Corbus reports FDA alignment on the CRB-701 path, as analysts flag upside tied to the head and neck cancer opportunity and obesity pipeline.

Latest Ratings for CRBP

DateFirmActionFromTo Oct 2020HC Wainwright & Co.MaintainsBuy Sep 2020HC Wainwright & Co.MaintainsBuy Sep 2020Roth CapitalDowngradesBuyNeutral

View More Analyst Ratings for CRBP

View the Latest Analyst Ratings

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent